Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Last week, Acxiom Corporation (ACXM) announced that it has stepped up its share repurchase plan to $150 million now. This was done with the clear intent of bolstering investor returns. Acxiom’s share repurchase program which started in August 2011, has bought back about 6.1 million shares since then for around $72 million. This accounts for nearly 7% of its total shares outstanding in the market.
The company’s incipient proactive advances towards returning value to investors accrues from its strong cash flow generation ability. Cash flow from operating activities came in at around $229.4 million for the fiscal year 2012 and Acxiom spent around $66 million to repurchase a total of 5.6 million shares during that time.
Looking ahead, management projects its earnings per share (EPS) to be within 55 cents to 65 cents for fiscal 2013. Strong product innovations, investment plans and management restructuring are expected to be the major highlights of the upcoming fiscal year for Acxiom.
However, there are big players prevalent in the industry that the company should always remain wary of. Ominous rivals in this regard include Unisys Corporation (UIS), CoStar Group Inc. (CSGP) and EPAM Systems, Inc. ((EPAM - Snapshot Report)).
The Zacks Consensus Estimates for the first quarter and fiscal 2013 stand at 10 cents per share and 61 cents per share, respectively. We currently have a long-term recommendation of ‘Neutral’ for the company’s stock. In the short run, we have a Zacks #3 Rank for the stock, which translates into a short-term rating of ‘Hold’.
Get the full Analyst Report on UIS - FREE
Get the full Snapshot Report on EPAM - FREE
Get the full Analyst Report on ACXM - FREE
Get the full Snapshot Report on CSGP - FREE